751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor

• Scott Daigle,
• Sunil Sharma,
• Xinyan Zhang,
• Martin Gutierrez,
• Patricia Fraser,
• David Sommerhalder,
• Scott Boiko,
• Esha A Gangolli,
• Bhaskar Srivastava,
• Frank G Basile,
• Marcus Noel,
• Amanda Hoerres,
• Nawaid Rana,
• Rama Balaraman

Affiliations

Scott Daigle

1Servier Pharmaceuticals, Boston, MA, United States

Sunil Sharma

2Stingray Therapeutics, Houston, TX

Xinyan Zhang

1 Medicine, Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA

Martin Gutierrez

5Hackensack University Medical Center, Hackensack, NJ, USA

Patricia Fraser

3Nimbus Therapeutics, Boston, MA, USA

David Sommerhalder

5NEXT Oncology, Texas Oncology, San Antonio, TX, USA

Scott Boiko

Nimbus Therapeutics, Boston, MA, USA

Esha A Gangolli

Nimbus Therapeutics, Boston, MA, USA

Bhaskar Srivastava

Nimbus Therapeutics, Boston, MA, USA

Frank G Basile

Nimbus Therapeutics, Boston, MA, USA

Marcus Noel

2Medstar Georgetown University Hospital, Washington, WA, USA

Amanda Hoerres

3Nimbus Therapeutics, Boston, MA, USA

Nawaid Rana

3Nimbus Therapeutics, Boston, MA, USA

Rama Balaraman

6Florida Cancer Affiliates-US Oncology, Ocala, FL, USA